Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for older adults or frail elderly patients with metastatic colorectal cancer - The randomized phase 2 AIO/IKF ELDERLY trial (AIO-KRK-0117/IKF 629).
Simplified chemotherapy regimens offer frail elderly patients with advanced colorectal cancer practical alternatives with clearer evidence than previous trial designs.
The AIO/IKF ELDERLY randomized Phase 2 trial directly addresses first-line treatment for frail elderly patients with metastatic colorectal cancer — a historically underrepresented and underserved population in oncology RCTs. Comparative data between a simplified regimen (aflibercept + 5-FU) and FOLFOX provide actionable guidance for a clinical scenario where treatment decisions are often empirical.
What the study was
- Study design
- Randomized Phase 2 clinical trial
- Population
- Older adults or frail elderly patients with metastatic colorectal cancer
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- European Journal of Cancer
Why it surfaced
Randomized Phase 2 trial specifically designed for frail elderly mCRC — a systematically underserved population lacking RCT data; provides near-actionable comparative data; published in Eur J Cancer.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.